Wild-type MLL infant ALL patients account for approximately 20% of all infant ALL cases. Although this group of patients generally fares better than MLL-rearranged infant ALL patients, their prognosis is still worse than that of non-infant pediatric B-ALL patients. Extensive characterization of this specific patient group largely remains unacknowledged. In this study we aim to clinically and molecularly characterize this patient group in order to find new openings for treatment optimization.
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Wild-type MLL infant ALL patients account for approximately 20% of all infant ALL cases. Although this group of patients generally fares better than MLL-rearranged infant ALL patients, their prognosis is still worse than that of non-infant pediatric B-ALL patients. Extensive characterization of this specific patient group largely remains unacknowledged. In this study we aim to clinically and molecularly characterize this patient group in order to find new openings for treatment optimization.
We report on a large cohort of 78 wild-type MLL infant ALL samples, using clinical parameters, arraycomparative genomic hybridization analysis, and gene expression profiling. The frequency of DNA copy number variations and molecular genetic lesions in genes involved in B-cell development are lower in wild-type MLL infant ALL compared to older children with ALL. Wild-type MLL infant ALL presented with higher WBC-counts and a more immature immunophenotype than pediatric (noninfant) B-ALL patients. The strongest predictor of outcome in wild-type MLL infant ALL was the level of MEIS1 expression, which may point to new opportunities for novel strategies in treating wild-type MLL infant ALL.
Acute lymphoblastic leukemia (ALL) in infants (<1 year of age) is a rare but highly aggressive type of leukemia, typically characterised by the presence of MLL-rearrangements occurring in ~80% of these patients. 1 The prognosis for MLL-rearranged infant ALL patients is highly unfavourable. 2 In contrast, infant ALL patients carrying wild-type (or germline) MLL genes fare significantly better, with reported event free survival (EFS) chances of 60%-74%. 1,2 However, these rates are much lower than the 5-year survival rates in older children with ALL, which are about 90%. 3 We recently showed that wild-type MLL infant ALL specifies a gene expression pattern that is different from both MLLrearranged infant ALL as well as from pediatric non-infant precursor B-ALL. 4 In an unsupervised clustering analysis, wild-type MLL infant ALL samples even appeared more closely related to MLLrearranged infant ALL than to pediatric precursor B-ALL cases. Also, infants ALL patients who do not carry MLL translocations share the same cytogenetic abnormalities as older children with ALL, albeit with a different distribution: a lower incidence of the favourable abnormalities ETV6-RUNX1 and high hyperdiploidy, and a higher incidence of unfavourable abnormalities, including BCR-ABL1.
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In the present study we aim to clinically and genetically characterize a relatively large cohort of wild- immunophenotypes, and generally responded well to a 7-day window of prednisone monotherapy (Table 1) .
Poor prednisone responses and a pro-B phenotype predict outcome in wild-type MLL infant ALL
Next we assessed the prognostic relevance of the above described predictive parameters in terms of disease-free survival (DFS), overall survival (OS), and cumulative incidence of relapse (CIR) after 5 years from diagnosis in wild-type MLL infant ALL patients (n=76) for whom clinical follow-up data was available ( Interestingly, high-level expression of MEIS1 is also tightly associated with prognostically unfavorable MLL-rearranged leukemias. 6, 7 Hence, the prognostic relevance of MEIS1 expression in wild-type MLL infant ALL patients may imply transformation events that to some extent resemble that of MLL-rearranged infant ALL cases. Furthermore, the strong influence on clinical outcome of MEIS1 expression suggests that infant ALL expressing high levels of MEIS1 represent a highly aggressive leukemia that require very few cooperative genetic lesion during leukemogenesis and/or leukemia maintenance.
Kang et al have shown that FLT3, IRX2 and TACC2 expression is highly predictive of event-free survival in infant ALL. 8 That we did not find a significant result from FLT3, IRX and TACC2 as predictors of outcome can be due to the fact that we have only used wild-type MLL patients or that our numbers are too limited to gain a significant result.
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Low number of submicroscopic DNA copy-number variations in wild-type MLL infant ALL
In order to detect submicroscopic deletions and amplifications in the DNA, we performed arraycomparative genomics hybridization (array-CGH) and multiplex ligation-dependent probe amplification (MLPA) on a cohort of wild-type MLL infant ALL patients (n=31 and n=32, respectively) for whom genomic DNA was available (Supplemental Table 2 ).
The results from array-CGH were compared with data from a group of pediatric (non-infant) B-ALL patients (n=115) ( Table 3) , selected with a relatively high frequency of B-others and low number of high hyperdiploid patients, which fact should be taken into account when interpreting the results.
The frequency of structural aberrations found by array-CGH (i.e. partial deletions/amplifications, and translocations) was much lower in wild-type MLL infants than in non-infant ALL patients (45% vs.
98%, respectively; p<0.001) ( Table 3 ). The frequency of patients with numerical aberrations (i.e. gain or loss of complete chromosomes) among wild-type MLL infant ALL patients (23%) was comparable to the frequency of numerical aberrations in non-infant pediatric ALL patients (29%).
MLPA analysis was done using specific probes for single gene alterations including CDKN2A, CDKN2B, IKZF1, PAX5 and ETV6 (Supplemental Table 3 ). In none of the wild-type MLL infant ALL samples (n=32) tested, alterations of IKZF1 were detected, whereas 17% of the pediatric non-infant B-ALL patients is known to carry an IKZF1 deletion. 9 A deletion of CDKN2A and CDKN2B on 9p21.3 was found in six (19%) of the infants. In contrast, in 35% and 34% of the pediatric non-infant ALL samples deletions of CDKN2A and CDKN2B were found, respectively. In four wild-type MLL infant ALL patients, deletions of PAX5 were present together with CDKN2A and CDKN2B, whereas in two infants the PAX5 deletion was the only observed abnormality as determined by MLPA. The incidence of ETV6 deletions was markedly lower in infants: 3% versus 26% of the pediatric precursor B-ALL patients (p=0.002), however, when ETV6-RUNX1 cases were excluded, only 11% of precursor B-ALL patients had ETV6 deletions (11%, p-value 0.2).
In conclusion, wild-type MLL infant ALL is clinically and molecularly another entity than pediatric analyzed data and edited the paper. R.P. and R.W.S. designed the research, analyzed the data and wrote the paper.
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Materials and Methods
Patient samples and sample preparation
Bone marrow and peripheral blood samples from wild-type MLL infant ALL patients (<1 year of age)
with newly diagnosed ALL were included from the international collaborative Interfant-99 1 and
Interfant-06 studies up till February 2010 (n=78). Out of these samples 36 samples were used for gene expression profiling, of which for thirty patients survival data was available. Array CGH was Leukemic samples preparation was essentially carried out as described before. 1 Samples from pediatric ALL patients older than 1 year (i.e., non-infants) were selected from our cell bank present at the Erasmus MC -Sophia Children's Hospital, Rotterdam, The Netherlands. All samples were freshly processed within 24 hours after sampling as previously described. 3 Briefly, mononuclear cells were isolated by density gradient centrifugation using Lymphoprep (NycomedPharma), and non-leukemic cells were removed using immunomagnetic beads. 4 All leukemia samples used in this study contained more than 90% leukemic cells, as determined morphologically on May-Grünwald-Giemsa (Merck)-stained cytospins.
RNA and DNA extraction
Total RNA and gDNA were extracted from a minimum of 5x10 6 leukemic cells using TRIzol reagent (Invitrogen Life Technologies) according to the manufacturer's instructions with minor modifications.
Quantification of DNA was performed using a spectrophotometer. Quantification and assessment of integrity of the extracted RNA was assessed using the Agilent 2100 Bio-analyzer (Agilent).
Gene expression profiling
The gene expression profiling (Affymetrix platform) data used in the present study has previously been published, 1 and has been deposited in the National Center for Biotechnology Information Gene Expression Omnibus 5 and is accessible via GEO Series accession number GSE19475. Additional unpublished gene expression data can be found under GEO accession number GSE58565. Raw array data were collectively normalized using variance-stabilizing normalization 6 and additionally corrected for batch effects using ComBat 7 . Removal of batch effects was visually verified by unsupervised principle component analysis. Differential gene expression was statistically evaluated using linear models for microarray analyses.
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Prednisone response
In vivo prednisone responses were determined after seven days of prednisone monotherapy (including a single intrathecal dose of methotrexate), prior to the initiation of combination chemotherapy. Patients were defined as good responders when <1000 leukemic blasts/μL were detectable in the peripheral blood. Patients still burdened with ≥1000 leukemic blasts/μL after prednisone monotherapy were defined as poor responders.
Oligo array-CGH
Oligo array-CGH (array competitive genomic hybridization) analysis was performed for the infant cohort using the human genome CGH Microarray 105k-A (Agilent Technologies, Palo Alto, CA) according to the manufacturer's protocol using a dye-swap experimental design to minimize false positive results, as previously described. 10 For the ALL-10 cohort Agilent SurePrint G3 180k arrays (Agilent Technologies, Palo Alto, CA) were used and no dye swap was done. Raw microarray image files were processed with Feature Extraction (Agilent Technologies, Santa Clara, CA). Results were analyzed using Agilent Genomic Workbench version 6.5 (Agilent Technologies, Santa Clara, CA).
Numerical aberrations were defined as loss or gain of a full chromosome. Structural aberrations were defined as any gain or loss of three or more subsequent probes with a minimum average absolute log ratio of 0.3 excluding known copy-number variations regions using track Hs_hg18_cnv_20090312.
Multiplex ligation-dependent probe amplification (MLPA) analysis and JAK2 mutations
MLPA was performed using the SALSA MLPA P335 ALL-IKZF1 probemix kit (MRC-Holland, Amsterdam, The Netherlands) according to the manufacturer's protocol. Mutations in JAK2 exon 16
were analyzed by polymerase chain reaction amplification and subsequent sequencing as described previously.
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TCF3-PBX1 PCR
TCF3-PBX1 was determined positive upon detection of a band after PCR using the following primers: forward: 5'-CACCAGCCTCATGCACAA-3', reverse: 5'-TCGCAGGAGATTCATCACG-3'.
Statistical analyses
Disease-free survival (DFS) was calculated from date of first remission to the date of event which included relapse, death in complete remission, or second malignancy, whichever occurred first.
Overall survival (OS) was calculated from the date of diagnosis to the date of death from any cause.
Observations of patients were censored at the date of last contact when no events were observed. Curves were compared using the log-rank test. Cumulative incidence of relapse (CIR) were estimated adjusting for competing risks of death and second malignancy were statistically analyzed by the Gray test. We used the Fisher exact test to assess the association between patients' characteristics and cohorts. All tests were two-sided. Survival analyses were performed using SAS 9.2 (SAS institute, Cary, NC, USA) and R 3.1.0 (R Core Team, R Foundation for Statistical
Computing, Vienna, Austria) at the Interfant Trial Center. The significance analysis of microarray (SAM) 12 was used to identify probe sets significantly associated with EFS, score was calculated with
